Form 4: Halozyme Therapeutics SVP, Chief Technical Officer Michael LaBarre Reports Stock Transactions

Michael J. LaBarre, SVP, Chief Technical Officer of Halozyme Therapeutics, reports multiple transactions involving company stock, including option exercises and sales, executed under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Michael J. LaBarre, the SVP, Chief Technical Officer of Halozyme Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
• The report covers transactions on October 15 and 16, 2024.
• LaBarre exercised options to purchase common stock at prices of $16.65 and $19.98.
• He also sold shares of common stock at weighted average prices of $53.743 and $53.259.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on March 9, 2023.
• Following these transactions, LaBarre directly owns 173,756 shares of Halozyme Therapeutics common stock.
• He also holds options to purchase 26,608 shares at $19.98 and 6,352 shares at $16.65.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports transactions executed under a pre-existing plan. There's no indication of positive or negative sentiment towards the company's prospects.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, suggesting they were planned well in advance and not based on immediate insider knowledge.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the trading activities of company insiders.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the impact is likely minimal given the relatively small number of shares involved.

Key Dates